Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessing Impact of Loco-regional Treatment on Survival in Metastatic Breast Cancer at Presentation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00193778
Recruitment Status : Completed
First Posted : September 19, 2005
Last Update Posted : October 8, 2020
Sponsor:
Information provided by (Responsible Party):
Dr Rajendra A. Badwe, Tata Memorial Centre

Brief Summary:
Traditionally metastatic breast cancer patients are not offered loco-regional treatment except in cases of fungation or bleeding. However, scientific evidence for such omission of loco-regional treatment in metastatic breast cancer patients is lacking. On one hand, studies have shown that removal of primary tumor at times leads to complete disappearance of metastases and improvement in survival in renal cell carcinoma patients. However, such studies have never been performed in other solid tumors. On the other hand, there is a strong body of evidence in experimental settings that show that removal of primary tumor allows growth of metastasis. There is lack of similar data in humans in clinical settings. Offering loco-regional treatment in metastatic breast cancer patients in a setting of randomized controlled trial will help in improving survival of such patients and understanding the natural history of breast cancer.

Condition or disease Intervention/treatment Phase
Cancer of the Breast Procedure: Surgery for breast cancer Other: No Loco-regional treatment Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 350 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Trial To Assess The Impact Of Loco-Regional Treatment On Survival Of Patients With Metastatic Breast Cancer At First Presentation
Study Start Date : February 2005
Actual Primary Completion Date : July 30, 2020
Actual Study Completion Date : July 30, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Loco Regional Treatment Arm (LRT)
Surgery for breast cancer. (MRM/BCT)
Procedure: Surgery for breast cancer
This group will receive standard loco-regional treatment i.e. surgery (modified radical mastectomy (MRM)/ Simple SMAC/BCT) +/- radiotherapy

Active Comparator: No Loco-regional Treatment Arm
No surgery for Breast cancer
Other: No Loco-regional treatment
This group will not receive any loco-regional treatment




Primary Outcome Measures :
  1. Overall survival [ Time Frame: 3 years ]
    Overall survival (OS) : Time interval between randomization and death

  2. Progression free survival [ Time Frame: 3 years ]
    PFS: Time interval between randomization and first date of progression of disease


Secondary Outcome Measures :
  1. Changes in VEGF, bFGF, Angiostatin and Endostatin [ Time Frame: 5 years ]
    The secondary endpoints include the assess of loco-regional treatment on levels



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Metastatic breast cancer at first presentation with an expected survival of at least one year

Exclusion Criteria:

  1. Patients who are not fit to receive anthracycline based chemotherapy.
  2. More than two visceral organ involvement.
  3. Multiple liver metastases with deranged liver function tests (SGOT/SGPT more than four times the upper normal limit).
  4. Locally static or progressive disease or systemically progressive disease as shown by repeat staging investigations guided by worsening symptoms.
  5. Ulceration/ fungation/ bleeding after completion of chemotherapy, which mandates surgery.
  6. Expected survival of less than six months after completion of chemotherapy.
  7. Unfit for anaesthesia due to metastatic disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00193778


Locations
Layout table for location information
India
Tata Memorial Hospital
Mumbai, Maharashtra, India, 400 012
Sponsors and Collaborators
Tata Memorial Hospital
Investigators
Layout table for investigator information
Principal Investigator: Rajendra A Badwe, MS (Surgery) Tata Memorial Hospital, Ernest Borges Road, Parel, Mumbai 400 012
Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Dr Rajendra A. Badwe, Director, Tata Memorial Centre
ClinicalTrials.gov Identifier: NCT00193778    
Other Study ID Numbers: TMH/153/2004
First Posted: September 19, 2005    Key Record Dates
Last Update Posted: October 8, 2020
Last Verified: October 2020
Keywords provided by Dr Rajendra A. Badwe, Tata Memorial Centre:
Metastatic breast cancer
Locoregional treatment
Survival
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases